Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...

The Chronic Lymphocytic Leukemia Market is set for significant expansion over the next decade. Valued at USD 5.4 billion in 2025, the market is projected to grow to USD 10.3 billion by 2035, ...

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration.

Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...

Blood Cancer United, which was formerly known as the Leukemia & Lymphoma Society, has created a way for blood cancer patients ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to UB-VV111 for the treatment of ...

A novel tool created by researchers at Weill Cornell Medicine and the University of Adelaide has improved the capacity to ...

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration. Here’s what ...

A UMAP graphical depiction of 45,963 cancer cells from patients whose chronic lymphocytic leukemia has transformed into a more aggressive type. The different colors represent different cell states (e.

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track ...